Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline-Review,-H1-2013/

1. RC
Reports Corner
Carcinomas – Pipeline Review, H1 2013

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for
Carcinomas, complete with latest updates, and special features
on late-stage and discontinued projects.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for
Carcinomas, complete with latest updates, and special features
on late-stage and discontinued projects. It also reviews key
players involved in the therapeutic development for Carcinomas.
Carcinomas - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor
presentations and featured press releases from
company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated
disease.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope
- A snapshot of the global therapeutic scenario for Carcinomas.
- A review of the Carcinomas products under development by
companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development
ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Carcinomas pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Identify and understand important and diverse types of
therapeutics under development for Carcinomas.
- Identify emerging players with potentially strong product
portfolio and design effective counter-strategies to gain
competitive advantage.
- Plan mergers and acquisitions effectively by identifying players
of the most promising pipeline.
- Devise corrective measures for pipeline projects by
understanding Carcinomas pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.

6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline.

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Carcinomas Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Carcinomas 11
Carcinomas Therapeutics under Development by Companies 13
Carcinomas Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Carcinomas Therapeutics – Products under Development by Companies 20
Carcinomas Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Carcinomas Therapeutics Development 22
Sequella, Inc. 22
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Merck & Co., Inc. 25
Takara Holdings Inc. 26
Aduro BioTech 27
Bayer AG 28
Momenta Pharmaceuticals, Inc. 29

9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
PCI Biotech AS 30
Nanobiotix 31
Cancer Research Technology Limited 32
Spectrum Pharmaceuticals, Inc. 33
Telormedix SA 34
Cellceutix Corporation 35
Viventia Biotechnologies Inc. 36
Lytix Biopharma AS 37
Carcinomas – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 45
cetuximab - Drug Profile 45

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 45
Mechanism of Action 45
R&D Progress 45
cixutumumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ridaforolimus - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(amphinex + bleomycin sulfate) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
M-402 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ramucirumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ramucirumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SQ-109 - Drug Profile 69
Product Description 69
Mechanism of Action 69

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 69
SPI-1620 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
imiquimod - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
oportuzumab monatox - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Kevetrin - Drug Profile 77
Product Description 77

13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 77
R&D Progress 77
HF-10 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
NPI-1342 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MOC31-PE - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
LTX-315 - Drug Profile 83

14. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 83
Mechanism of Action 83
R&D Progress 83
aspirin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
nelfinavir mesylate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
GV-1001 + LTX-315 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86

15. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
lambrolizumab - Drug Profile 90
Product Description 90
Mechanism of Action 90

16. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 90
cidofovir - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
BAY-94-9343 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ANZ-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
LY-2510924 - Drug Profile 95
Product Description 95

17. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 95
R&D Progress 95
dasatinib + [erlotinib hydrochloride] + [gemcitabine hydrochloride] - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
interleukin-15 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
interferon alfa-2b biosimilar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Anti-S100A4 Monoclonal Antibody - Drug Profile 100

18. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 100
Mechanism of Action 100
R&D Progress 100
NBTX-IV - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Platinum Based Compounds - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
PMA-104R - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103

19. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Carcinomas Therapeutics – Drug Profile Updates 104
Carcinomas Therapeutics – Discontinued Products 126
Carcinomas Therapeutics - Dormant Products 127
Carcinomas – Product Development Milestones 130
Featured News & Press Releases 130
May 01, 2013: GSK Announces FDA Extension Of PDUFA Date For Trametinib By Three Months 130
Jun 29, 2012: Topotarget Announces Top-Line Results From Phase II Trial Of Belinostat For Treatment Of
Cancer 130
Oct 04, 2011: Fresenius Biotech Obtains Reimbursement Approval For Removab Antibody In Belgium 131
Sep 19, 2011: Spectrum Announces Positive First Part Of Phase I Study Results Of SPI-1620 In
Carcinomas 131
Jun 14, 2011: ImmunoGen Earns Milestone With BAY 94-9343 IND Submission 132
Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 133
Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 134
May 26, 2011: ImmunoGen Announces Clinical Presentation Of IMGN901 At ASCO 2011 Annual Meeting
135

20. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Apr 04, 2011: ImmunoGen Announces First Data For New Therapeutic For Ovarian Cancer And Other
Carcinomas 135
Apr 04, 2011: Curis Announces Investigator-Initiated Phase II Study Results Presented At 102nd AACR
Annual Meeting 2011 136
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 139
Disclaimer 139

21. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline-
Review,-H1-2013/

22. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com